FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200390596> ?p ?o ?g. }

• W4200390596 endingPage "100089" @default.
• W4200390596 startingPage "100089" @default.
• W4200390596 abstract "PurposeGain of chromosome 6p has been associated with poor ocular survival in retinoblastoma and histopathologic grading of anaplasia with increased risk of metastatic spread and death. This study examined the correlation between these factors and other chromosomal abnormalities as well as results of whole genome sequencing, digital morphometry, and progression-free survival.DesignRetrospective cohort study from 2 United States tertiary referral centers.ParticipantsForty-two children who had undergone enucleation for retinoblastoma from January 2000 through December 2017.MethodsStatus of chromosomes 6p, 1q, 9q, and 16q was evaluated with fluorescence in situ hybridization, the degree of anaplasia and presence of histologic high-risk features were assessed by ocular pathologists, digital morphometry was performed on scanned tumor slides, and whole genome sequencing was performed on a subset of tumors. Progression-free survival was defined as absence of distant or local metastases or tumor growth beyond the cut end of the optic nerve.Main Outcome MeasuresCorrelation between each of chromosomal abnormalities, anaplasia, morphometry and sequencing results, and survival.ResultsForty-one of 42 included patients underwent primary enucleation and 1 was treated first with intra-arterial chemotherapy. Seven tumors showed mild anaplasia, 19 showed moderate anaplasia, and 16 showed severe anaplasia. All tumors had gain of 1q, 18 tumors had gain of 6p, 6 tumors had gain of 9q, and 36 tumors had loss of 16q. Tumors with severe anaplasia were significantly more likely to harbor 6p gains than tumors with nonsevere anaplasia (P < 0.001). Further, the hematoxylin staining intensity was significantly greater and that of eosin staining significantly lower in tumors with severe anaplasia (P < 0.05). Neither severe anaplasia (P = 0.10) nor gain of 6p (P = 0.21) correlated with histologic high-risk features, and severe anaplasia did not correlate to RB1, CREBBP, NSD1, or BCOR mutations in a subset of 14 tumors (P > 0.5). Patients with gain of 6p showed significantly shorter progression-free survival (P = 0.03, Wilcoxon test).ConclusionsGain of chromosome 6p emerges as a strong prognostic biomarker in retinoblastoma because it correlates with severe anaplasia, quantifiable changes in tumor cell staining characteristics, and extraocular spread. Gain of chromosome 6p has been associated with poor ocular survival in retinoblastoma and histopathologic grading of anaplasia with increased risk of metastatic spread and death. This study examined the correlation between these factors and other chromosomal abnormalities as well as results of whole genome sequencing, digital morphometry, and progression-free survival. Retrospective cohort study from 2 United States tertiary referral centers. Forty-two children who had undergone enucleation for retinoblastoma from January 2000 through December 2017. Status of chromosomes 6p, 1q, 9q, and 16q was evaluated with fluorescence in situ hybridization, the degree of anaplasia and presence of histologic high-risk features were assessed by ocular pathologists, digital morphometry was performed on scanned tumor slides, and whole genome sequencing was performed on a subset of tumors. Progression-free survival was defined as absence of distant or local metastases or tumor growth beyond the cut end of the optic nerve. Correlation between each of chromosomal abnormalities, anaplasia, morphometry and sequencing results, and survival. Forty-one of 42 included patients underwent primary enucleation and 1 was treated first with intra-arterial chemotherapy. Seven tumors showed mild anaplasia, 19 showed moderate anaplasia, and 16 showed severe anaplasia. All tumors had gain of 1q, 18 tumors had gain of 6p, 6 tumors had gain of 9q, and 36 tumors had loss of 16q. Tumors with severe anaplasia were significantly more likely to harbor 6p gains than tumors with nonsevere anaplasia (P < 0.001). Further, the hematoxylin staining intensity was significantly greater and that of eosin staining significantly lower in tumors with severe anaplasia (P < 0.05). Neither severe anaplasia (P = 0.10) nor gain of 6p (P = 0.21) correlated with histologic high-risk features, and severe anaplasia did not correlate to RB1, CREBBP, NSD1, or BCOR mutations in a subset of 14 tumors (P > 0.5). Patients with gain of 6p showed significantly shorter progression-free survival (P = 0.03, Wilcoxon test). Gain of chromosome 6p emerges as a strong prognostic biomarker in retinoblastoma because it correlates with severe anaplasia, quantifiable changes in tumor cell staining characteristics, and extraocular spread." @default.
• W4200390596 created "2021-12-31" @default.
• W4200390596 creator A5006347854 @default.
• W4200390596 creator A5025834624 @default.
• W4200390596 creator A5030943174 @default.
• W4200390596 creator A5056669160 @default.
• W4200390596 creator A5057215721 @default.
• W4200390596 creator A5057277785 @default.
• W4200390596 date "2022-03-01" @default.
• W4200390596 modified "2023-10-17" @default.
• W4200390596 title "Gain of Chromosome 6p Correlates with Severe Anaplasia, Cellular Hyperchromasia, and Extraocular Spread of Retinoblastoma" @default.
• W4200390596 cites W1228495643 @default.
• W4200390596 cites W1829980845 @default.
• W4200390596 cites W1844379777 @default.
• W4200390596 cites W1919257374 @default.
• W4200390596 cites W1972944860 @default.
• W4200390596 cites W1982196255 @default.
• W4200390596 cites W2005698028 @default.
• W4200390596 cites W2025712151 @default.
• W4200390596 cites W2028142836 @default.
• W4200390596 cites W2032839233 @default.
• W4200390596 cites W2034806228 @default.
• W4200390596 cites W2038858587 @default.
• W4200390596 cites W2069890240 @default.
• W4200390596 cites W2075858335 @default.
• W4200390596 cites W2103441770 @default.
• W4200390596 cites W2106578986 @default.
• W4200390596 cites W2112567075 @default.
• W4200390596 cites W2112934711 @default.
• W4200390596 cites W2114031931 @default.
• W4200390596 cites W2119180969 @default.
• W4200390596 cites W2120033395 @default.
• W4200390596 cites W2128016314 @default.
• W4200390596 cites W2139100560 @default.
• W4200390596 cites W2162139554 @default.
• W4200390596 cites W2168133698 @default.
• W4200390596 cites W2287628440 @default.
• W4200390596 cites W2344376220 @default.
• W4200390596 cites W2404113298 @default.
• W4200390596 cites W2581082771 @default.
• W4200390596 cites W2767410506 @default.
• W4200390596 cites W2771177310 @default.
• W4200390596 cites W2810447451 @default.
• W4200390596 cites W2883052277 @default.
• W4200390596 cites W2885182378 @default.
• W4200390596 cites W2943301866 @default.
• W4200390596 cites W2952481429 @default.
• W4200390596 cites W2980804896 @default.
• W4200390596 cites W3007815704 @default.
• W4200390596 cites W3013166479 @default.
• W4200390596 cites W3026157420 @default.
• W4200390596 cites W3034817922 @default.
• W4200390596 cites W3081065365 @default.
• W4200390596 cites W3081814631 @default.
• W4200390596 cites W3200378118 @default.
• W4200390596 cites W4211146114 @default.
• W4200390596 cites W4247053599 @default.
• W4200390596 cites W4250644275 @default.
• W4200390596 cites W93281603 @default.
• W4200390596 doi "https://doi.org/10.1016/j.xops.2021.100089" @default.
• W4200390596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36246172" @default.
• W4200390596 hasPublicationYear "2022" @default.
• W4200390596 type Work @default.
• W4200390596 citedByCount "2" @default.
• W4200390596 countsByYear W42003905962022 @default.
• W4200390596 countsByYear W42003905962023 @default.
• W4200390596 crossrefType "journal-article" @default.
• W4200390596 hasAuthorship W4200390596A5006347854 @default.
• W4200390596 hasAuthorship W4200390596A5025834624 @default.
• W4200390596 hasAuthorship W4200390596A5030943174 @default.
• W4200390596 hasAuthorship W4200390596A5056669160 @default.
• W4200390596 hasAuthorship W4200390596A5057215721 @default.
• W4200390596 hasAuthorship W4200390596A5057277785 @default.
• W4200390596 hasBestOaLocation W42003905961 @default.
• W4200390596 hasConcept C104317684 @default.
• W4200390596 hasConcept C141071460 @default.
• W4200390596 hasConcept C142724271 @default.
• W4200390596 hasConcept C143998085 @default.
• W4200390596 hasConcept C188261085 @default.
• W4200390596 hasConcept C2776577112 @default.
• W4200390596 hasConcept C2780263296 @default.
• W4200390596 hasConcept C54355233 @default.
• W4200390596 hasConcept C71924100 @default.
• W4200390596 hasConcept C86803240 @default.
• W4200390596 hasConceptScore W4200390596C104317684 @default.
• W4200390596 hasConceptScore W4200390596C141071460 @default.
• W4200390596 hasConceptScore W4200390596C142724271 @default.
• W4200390596 hasConceptScore W4200390596C143998085 @default.
• W4200390596 hasConceptScore W4200390596C188261085 @default.
• W4200390596 hasConceptScore W4200390596C2776577112 @default.
• W4200390596 hasConceptScore W4200390596C2780263296 @default.
• W4200390596 hasConceptScore W4200390596C54355233 @default.
• W4200390596 hasConceptScore W4200390596C71924100 @default.
• W4200390596 hasConceptScore W4200390596C86803240 @default.
• W4200390596 hasFunder F4320306811 @default.
• W4200390596 hasFunder F4320312354 @default.
• W4200390596 hasFunder F4320312361 @default.
• W4200390596 hasFunder F4320318349 @default.

• next